Family Co., Ltd.

▎药明康德内容团队报道公开资料显示，在刚刚过去的4月份，多家中国医疗器械公司宣布迎来融资进展，这些公司正在专注于研发手术机器人、人工心脏、近视防控产品、新材料人工晶状体、过敏性鼻炎家用智能化医疗产品、蓝极光手术系统、脊髓损伤治疗产品等等。本文将分享其中12家新锐公司的基本信息，仅供读者参阅。术锐机器人研发领域：单孔腔镜手术机器人等投资机构：正心谷资本、德诺资本、新毅投资、三亚翠湖、源星资本、国投招商等4月4日，术锐机器人公司宣布完成C3轮数亿元人民币的融资，由正心谷资本领投，德诺资本、新毅投资、三亚翠湖跟投，并获得了源星资本、国投招商等原股东支持。术锐机器人成立于2014年，致力于研发腔镜手术机器人系统等产品，公司创始人为上海交通大学徐凯教授。据悉，该公司依托“对偶连续体机构”这一创新性设计，推出搭载镍钛合金蛇形手术臂的术锐单孔腔镜手术机器人，其可完成经典高难度单孔术式，让患者在较小创伤的同时更大程度保留器官功能。该产品已经于2020年进入中国国家药监局（NMPA）创新医疗器械特别审查程序（即“绿色通道”）。嘉奥科技研发领域：新一代智能骨科手术机器人投资机构：重庆巴南基金4月11日消息，嘉奥科技（Keyinbot）宣布完成数千万元A+轮融资，由深投控旗下投控东海管理的重庆巴南基金领投。嘉奥科技成立于2017年，致力于打造新一代智能骨科手术机器人。该公司开发的第一代骨科手术机器人主要应用于脊柱手术领域，目前已经完成临床试验。从临床数据看，该设备可以实现脊柱手术全流程智能化，经检测的系统精度达0.9毫米以下，具有一定的优势。该公司第二代产品为一款超小型骨科手术机器人，大幅度减小整体设备的体积与重量。蓝极医疗研发领域：蓝极光手术系统、光生物调节设备等投资机构：合肥中合欧普医疗健康产业基金、陕投成长基金4月12日消息，蓝极医疗宣布完成数千万元A+轮融资，由合肥中合欧普医疗健康产业基金领投、陕投成长基金参与投资。蓝极医疗成立于2016年，专注于高端激光医疗领域。该公司研发的30W蓝激光手术系统已经获NMPA三类医疗器械注册证，大功率的200W蓝激光手术系统也获得批准上市。蓝激光手术系统具有汽化效率高、热损伤低、术式简单易掌握等优点，可为前列腺、膀胱、口腔、子宫等自然腔道疾病提供创新手术解决方案。本轮融资将用于该公司蓝激光微创、光动力诊疗一体化设备、光生物调节等系列创新产品的研发、临床研究等。侏罗纪生物科技研发领域：再生医学相关的生物技术、生物材料等投资机构：一家医疗器械产业公司4月14日，侏罗纪生物宣布获得5000万元战略投资，投资方为一家医疗器械产业公司。侏罗纪生物成立于2019年，主要从事再生医学相关的生物技术、生物材料、干细胞等的研发和转化。该公司拟用于战创伤、急救止血的水触发医用封堵胶体系——聚乙二醇粉末敷料已经通过医疗器械注册型检与生物学评价实验。动物实验显示，该产品可在1分钟内实现动脉出血的应急止血，避免受伤人员、患者因出血量过大危及生命。核心医疗研发领域：针对心衰患者的人工心脏融资轮次：正心谷资本、景林投资4月17日消息，核心医疗宣布再获近2亿元C+轮融资，由正心谷资本领投、景林投资跟投。这是该公司继2022年12月完成数亿元C轮融资仅三个多月后，再获资本加码。核心医疗成立于2016年，致力于为心衰患者提供创新的机械循环支持（俗称“人工心脏”）解决方案，公司创始人兼首席执行官（CEO）为余顺周博士。根据核心医疗新闻稿，该公司此前陆续获中金资本、高瓴创投、基石资本等十余家投资机构的近10亿元融资，并已开启IPO申报之路。据悉，核心医疗已研发出全新一代超小型全磁悬浮人工心脏（全磁悬浮离心式左心室辅助系统Corheart 6），可用于治疗终末期心力衰竭。该产品血泵重量仅90g，适用于体表面积大于1.0 ㎡的小体型成人和儿童患者，其术中植入侵犯性小，术后患者恢复快。中景纬视研发领域：近视防控产品线以及干眼穿戴设备等投资机构：水木创投、清石资本4月17日，中景纬视宣布完成数千万元天使轮融资，由水木创投领投，清石资本跟投。中景纬视立足于眼科消费类医疗级专业领域，正在研发近视防控产品线，以及适用于干眼的可穿戴设备、数字化眼视光周边等产品。该公司的近视防控产品S.T.O.P. KIT在近视防控原理上做了升级，在设计之初便引入了时间和空间因素，采用的光学设计可随着时间、空间的变化来提供方向性提示或光学停止信号，将随时间变化导致的疗效饱和度降到最低，以达到减慢、改善、控制、抑制或减少近视发展的速度。该产品有望解决传统离焦镜近视防控效果会随着时间衰减的痛点。敏舒科技研发领域：过敏性鼻炎家用智能化医疗产品投资机构：溪山天使基金4月18日消息，敏舒科技获溪山天使基金数百万元天使轮融资。此轮融资将用于该公司产品研发、医疗认证及团队建设。敏舒科技成立于2021年，专注于儿童鼻炎，是一家过敏性鼻炎家用智能化医疗产品和服务供应商。据悉，该公司在温度控制、压力控制、颗粒控制、药液浓度、气流浓度等技术上有较深厚的技术积累，研发的鼻炎治疗产品避免了传统疗法副作用大，舒适性差的问题，更易为儿童接受，尤其适合中重度过敏性鼻炎，干燥性鼻炎和血管运动型鼻炎。智枢生物科技研发领域：脊髓损伤治疗产品投资机构：中科先进基金等4月18日消息，智枢生物科技宣布完成3000万元人民币Pre-A轮融资，由中科先进基金及相关方投资。智枢生物科技成立于2021年，由深圳光明脑科学技术产业创新中心孵化，致力于中枢神经损伤修复产品研发。该公司借助生物材料的支架作用，以及生物材料对神经营养因子的缓释功能，发挥神经营养因子的群体效应，旨在改善损伤局部微环境，充分调动机体内在的再生能力，提高中枢神经系统损伤后再生的质量。这种模式有望从根本解决中枢神经损伤修复的医学难题。该公司开发的脊髓损伤治疗全新产品即将开展注册型临床试验。惠凯医疗研发领域：泌尿外科微创器械等投资机构：北京纳通科技集团4月19日消息，惠凯医疗宣布完成由北京纳通科技集团独家投资的数千万人民币A+轮融资。惠凯医疗成立于2018年，专注于泌尿外科领域，产品涉及前列腺增生、结石管理，以及尿失禁、泌尿系肿瘤和新材料等多个细分领域。据悉，惠凯医疗核心产品UroStent是一款前列腺支架系统，它无需进行全麻、无需使用膀胱镜进行定位及释放，使用便捷，术者可以在5分钟以内完成置入，有望极大缩短术前准备的时间及手术操作时间，实现日间手术或门诊手术。该产品目前已启动临床试验。眼得乐医疗研发领域：新材料人工晶状体投资机构：元生创投、中欧盛世、太盟投资集团4月23日，眼得乐医疗（Eyedeal Medical）宣布完成亿元人民币B轮融资，由元生创投领投，中欧盛世、太盟投资集团跟投。眼得乐医疗成立于2015年，核心产品为治疗白内障的人工晶状体。据悉，该公司采用“交联聚烯烃”医用高分子材料研发的新一代新材料人工晶状体已经进入NMPA创新医疗器械特别审查程序（绿色通道）。研究证明，交联聚烯烃人工晶状体具有更好的生物相容性、材料稳定性和良好的光学、力学等特性，可在保持微切口的同时实现大光学面，降低眩光的发生，为白内障患者带来更安全长效的临床益处和体验。此外，眼得乐医疗还正在利用疏水性丙烯酸酯材料平台研制针对白内障患者的人工晶状体。普立蒙研发领域：医疗级别可吸收高分子材料投资机构：国投创合、华泰紫金、新工产投、南京创投、东南美达、双创股份、雅惠投资、荣振投资4月24日消息，南京普立蒙医疗科技有限公司（简称“普立蒙”）宣布完成近两亿元B轮融资，由国投创合领投，华泰紫金、新工产投、南京创投、东南美达、双创股份跟投，原股东雅惠投资、荣振投资追加投资。普立蒙成立于2016年，致力于研发医疗级别可吸收高分子材料。该公司的倒刺缝线产品采用聚对二氧环己酮（PPDO）高分子材料经特殊工艺加工而成，可360度螺旋倒刺切割，缝合过程无需打结，降解周期约180天，能使微创手术缝合更加简便易行，大大缩短缝合时间。普立蒙还根据不同临床外科场景使用需求，开发了系列特殊缝线，包括较高技术壁垒的鱼骨线等。登特菲医疗研发领域：口腔智能设备及全产业链数字化云平台投资机构：君联资本、鑫元成长基金4月25日消息，登特菲医疗宣布完成亿元B轮融资，由君联资本和鑫元成长基金联合投资。登特菲医疗成立于2019年，以数字化影像技术为核心，专注于口腔智能设备及全产业链数字化云平台的研制。该公司已开发完成了3D口腔显微镜、EMOVE显微镜、牙科影像扫描仪、口腔CBCT（锥形束CT）等多款设备，并在2022推出了超大视野昆仑CBCT。除了上述公司，还有其它创新医疗器械公司也在今年4月完成融资，限于篇幅，本文不再一一介绍。希望在资本的助力下，这些公司可以加快创新产品的研发进度，早日为广大患者带来新的治疗选择。 参考资料：（可上下滑动查看） [1]喜报｜术锐机器人完成C3轮融资.Retrieved Apr 4，2023, From https://mp.weixin.qq.com/s/rxYfuQhxNdRZRM8pF83JmA[2]嘉奥科技完成数千万A+轮融资，助力手术机器人智能化及普及化 | 松禾Portfolio. Retrieved Apr 11，2023, From  https://mp.weixin.qq.com/s/Ad6sgcO2tIO1zJMRxXumTw[3]【会员动态】中科创星天使轮项目「蓝极医疗」完成数千万元A+轮融资｜创星portfolio. Retrieved Apr 12，2023, From  https://mp.weixin.qq.com/s/W-GvIGoU7JE6ybb2vOXUtg[4]侏罗纪生物科技获五千万战略投资，将聚焦创新医疗器械的深度开发.Retrieved Apr 14，2023, From https://mp.weixin.qq.com/s/eep_Dlf84V1lLYDeB2cOEw[5]荷塘新闻｜荷塘创投天使孵化企业核心医疗完成近2亿元C+轮融资，以创新力量带领“中国心”走向全球.Retrieved Apr 19，2023, From https://mp.weixin.qq.com/s/xb3-Aw2hUDSYxVIQu2i5XQ[6]近视防控首创S.T.O.P®KIT技术完成融资，启动全球临床.Retrieved Apr 17，2023, From https://mp.weixin.qq.com/s/z2n-16U2BNNtfrNaqCmXUw[7]医药行业一周投融资动态——加速生命科学领域创新发展，生工生物获20亿融资｜承树专题.Retrieved Apr 24，2023, From https://mp.weixin.qq.com/s/1RLLE3EyZWHtzjI8rZueLg[8]智枢生物科技获3000万Pre-A轮融资，助力脊髓神经再生新发展. Retrieved Apr 18， 2023, from https://mp.weixin.qq.com/s/UK124a-LxURtDHyS6NQj6A[9]【首发】惠凯医疗完成数千万A+轮投资，加速新型尿道支架系统临床试验的推进.Retrieved Apr 19，2023, From https://mp.weixin.qq.com/s/0SkoFcm3CtjYVA-VbijPug[10]元生创投Family | 眼得乐完成亿元人民币B轮融资， 加快新一代创新材料人工晶状体商业化布局. Retrieved Apr 23 , 2023, from https://mp.weixin.qq.com/s/o-26f24rYvKTKsMFpWqeOw[11]普立蒙完成近两亿元B轮融资， 加速可降解高分子医疗器械产业链布局 | 取势交易. Retrieved Apr 24 , 2023, from https://mp.weixin.qq.com/s/scyBi2-gwl6nrUJXiaQZJA[12]【已投企业动态】口腔设备及数字化平台企业登特菲完成亿元B轮融资. Retrieved Apr 24 , 2023, from https://mp.weixin.qq.com/s/1c0jla6FMH7q2T1ZyD445本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「医药观澜」微信公众号留言联系我们。其他合作需求，请联系wuxi_media@wuxiapptec.com。免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。

MISSION, Kan., Dec. 12, 2022 /PRNewswire/ -- (Family Features) Millions of people in the United States use sharps to manage short-term or chronic conditions. Sharps are needles or devices that puncture the skin to dispense medication. For many existing sharps users and people using sharps for the first time, disposal can be confusing, especially while traveling. Holiday travel requires sharps users to be educated on local rules governing safe disposal. Continue Reading Photo courtesy of Getty Images A resource called SafetyIsThePoint.org helps people learn how to safely discard their used sharps and find disposal locations across the United States. The website features a clickable map and ZIP code search that explains disposal rules by location to help travelers comply with local regulations, no matter where they are. Additionally, there are short videos explaining what sharps are and how to manage their disposal at home and on the road. Free printable resources, a step-by-step guide for at-home sharps disposal and a disposal location finder in every state are available on the website for sharps users, health care providers, patient educators and advocates. The resources can also be downloaded and sent to family members and friends ahead of travel. No matter if you are traveling by plane, train, car or staying home this holiday season, it's important to know how to safely dispose of used sharps. SafetyIsThePoint.org can help. Learn more about the rules of safe sharps disposal this holiday season at SafetyIsThePoint.org. Photo courtesy of Getty Images Michael French [email protected] 1-888-824-3337 editors.familyfeatures.com About Family Features Editorial Syndicate A leading source for high-quality food, lifestyle and home and garden content, Family Features provides readers with topically and seasonally relevant tips, takeaways, information, recipes, videos, infographics and more. Find additional articles and information at Culinary.net and eLivingToday.com. SOURCE Family Features Editorial Syndicate

Built on Algorand, and in partnership with the Government of Maharashtra in India, NFT technology will be used for storing personal health data for the first time VOORHEES, N.J. and MUMBAI, India, Dec. 7, 2022 /PRNewswire/ -- MAPay, a global healthcare technology firm with a focus on decentralized payment networks, unveiled its partnership with the Ministry of Public Health and Family Welfare in the Government of Maharashtra, India, to provide NFT technology that will store personal health data on the blockchain for the first time. Built on Algorand, the first deployment will introduce upwards of 100 million NFTs for this purpose. MAPay will use its proprietary NFT technology to enable secure, decentralized storage. This application for NFTs will help eliminate intermediaries in the healthcare system that routinely cause bottlenecks, introduce risk, and drive up costs for all parties – including patients; public, private, and government health providers; insurance companies; and banks. With key healthcare partnerships in the U.S. and beyond, MAPay will use the Algorand blockchain as the backbone for future advancements in the sector. In collaboration with leading organizations focused on advancing interoperability and payments in healthcare, MAPay seeks to implement a patient-driven data exchange that aids in population health management and better overall outcomes. The firm is working alongside large pharma, insurers, health systems, banks and governments. "Our vision and passion is aligned with our global partners: to democratize healthcare. We want to truly transform Healthcare to Humancare," said MAPay CEO Michael Dershem. "This use case is a perfect real-world application of blockchain technology. The impact on individuals and society as a whole is what we wake up to accomplish every day." The Algorand blockchain has experienced zero downtime since launch. Its sustainable, carbon-negative technology offers immediate transaction finality, consensus and network-level security, and advanced smart contracts built for scalability. The open, public infrastructure powers participation, transparency, and efficiency with real-world applications spanning many industries, including healthcare, finance, humanitarian aid, government, sports, entertainment, and more. "As a clinician and a participant in shaping public health policy, I recognize the need for reliable integration and storage of clinical health records. This digital infrastructure is critical in building autonomous AI solutions, especially where accurate, accessible healthcare is not easily available," said Dr. Sabine Kapasi, UN Health Policy and Governance Strategy lead. "This technology is transformational. Its transference and acceptance globally once seemed unimaginable; but now it is within reach." About MAPay MAPay is a global healthcare fintech company that is deploying distributed ledger technology to power smart contracts, transacting secure medical solutions. The company has developed a hybrid architecture of both centralized and decentralized protocols for multi-party medical payments and HIPAA-compliant data exchange. MAPay is working in association with hospital networks, practice management systems, drug companies, insurance payers and government entities. The company is committed to empowering patients and healthcare providers by leveraging blockchain technology to improve and align incentives, reduce costs, and bring increased transparency and data exchange. The company believes in permissionable open-sourced system collaboration, and solution sets that are economically and socially impactful. For more information, please visit About Algorand Inc. Founded by Turing Award-winning cryptographer Silvio Micali, Algorand's high–performing Layer-1 blockchain is unparalleled for bringing fast, frictionless, and inclusive technologies to everyone. Algorand is reshaping every industry–from TradFi and DeFi to new creator economies and beyond. With an extraordinary commitment to interoperability and consistent delivery, its sustainable technology powers more participation, transparency, and efficiency for all. As the technology of choice for 2,000+ global organizations, the Algorand ecosystem is transforming the next generation of financial products, protocols and exchange of value. For more information, visit . Media Contact: [email protected] SOURCE Algorand